Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
AssigneeThe Regents of the University of California
InventorsRichard S. Stephens, Diane Kawa
Life of this patent
Estimating the term…
Abstract
The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.
Claims32
A method for producing antibodies that specifically bind PorB polypeptide, the method comprising:
- administering to a mammalian subject an immunogenic composition comprising at least one PorB polypeptide having a neutralizing epitope, wherein the polypeptide is other than a full-length PorB polypeptide;
- wherein said administering results in production of an antibody that specifically binds PorB polypeptide.
A method for eliciting an immune response against Chlamydia in a mammalian subject, the method comprising:
- administering to a mammalian subject an immunogenic composition comprising a PorB polypeptide in an amount sufficient to elicit an immune response;
- wherein the immunogenic composition comprises at least one PorB polypeptide having a neutralizing epitope, wherein the polypeptide is other than a full-length PorB polypeptide.
A method for eliciting an immune response against Chlamydia in a mammalian subject, the method comprising:
- administering to a mammalian subject an immunogenic composition in an amount sufficient to elicit an immune response, wherein the immunogenic composition comprises at least one nucleic acid for expression in the subject, the nucleic acid encoding at least one PorB polypeptide having a neutralizing epitope, and wherein the polypeptide is other than a full-length PorB polypeptide.
An isolated PorB polypeptide composition comprising:
- an isolated polypeptide comprising a PorB neutralizing epitope domain, said PorB neutralizing domain being selected from the group consisting of ND1 (SEQ ID NO:
- 7), ND2 (SEQ ID NO:
- 8), ND3 (SEQ ID NO:
- 9), and ND4 (SEQ ID NO:
- 10), wherein the polypeptide is present in the composition in an amount effective to induce an immune response in a subject, and wherein the polypeptide is other than a full-length PorB polypeptide;
- and
- a pharmaceutically acceptable carrier.
A composition comprising:
- an isolated polynucleotide comprising a sequence encoding a PorB polypeptide comprising a neutralizing epitope, wherein the polypeptide is other than a full-length PorB polypeptide, the neutralizing epitope being selected from the group consisting of ND1 (SEQ ID NO:
- 7), ND2 (SEQ ID NO:
- 8), ND3 (SEQ ID NO:
- 9), and ND4 (SEQ ID NO:
- 10), wherein the polynucleotide is operably linked to a promoter suitable for expression in a host cell;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.